<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Terminology and outcomes definitions for thrombotic thrombocytopenic purpura (TTP)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Terminology and outcomes definitions for thrombotic thrombocytopenic purpura (TTP)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Terminology and outcomes definitions for thrombotic thrombocytopenic purpura (TTP)</div><div class="cntnt"><table cellspacing="0"><colgroup width="30%"></colgroup><colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="2">Syndromes</td> </tr> <tr> <td class="indent1">Thrombotic microangiopathy (TMA)</td> <td>Condition in which small vessel microthrombi form and cause thrombocytopenia (platelet count &lt;150,000/microL) and microangiopathic hemolytic anemia (MAHA; schistocytes and evidence of hemolysis)</td> </tr> <tr> <td class="indent1">Thrombotic thrombocytopenic purpura (TTP)</td> <td>TMA caused by severe deficiency of the ADAMTS13 protease, which cleaves large VWF multimers</td> </tr> <tr> <td class="indent2"> <ul> <li>Immune TTP</li> </ul> </td> <td>Acquired TTP caused by an autoantibody against ADAMTS13</td> </tr> <tr> <td class="indent2"> <ul> <li>Hereditary TTP</li> </ul> </td> <td>Genetic condition caused by biallelic variants in the <em>ADAMTS13</em> gene</td> </tr> <tr> <td class="subtitle1_left" colspan="2">Outcomes of therapy for immune TTP</td> </tr> <tr> <td class="indent1">Clinical response</td> <td> <p>Resolution of thrombocytopenia and hemolysis</p> <p class="indent1">-and-</p> Cessation of clinical deterioration</td> </tr> <tr> <td class="indent1">Remission</td> <td>Sustained response after stopping TPE and/or anti-VWF therapy</td> </tr> <tr> <td class="indent2"> <ul> <li>Clinical remission</li> </ul> </td> <td> <p>Sustained clinical response for ≥30 days</p> <p class="indent1">-or-</p> ADAMTS13 remission (partial or complete)</td> </tr> <tr> <td class="indent2"> <ul> <li>ADAMTS13 remission (partial)</li> </ul> </td> <td>ADAMTS13 activity ≥20% but below the assay's lower limit of normal</td> </tr> <tr> <td class="indent2"> <ul> <li>ADAMTS13 remission (complete)</li> </ul> </td> <td>ADAMTS13 activity above the assay's lower limit of normal</td> </tr> <tr> <td class="indent1">Relapse</td> <td>Clinical and/or laboratory deterioration following remission</td> </tr> <tr> <td class="indent2"> <ul> <li>Clinical relapse</li> </ul> </td> <td>Recurrence of thrombocytopenia following a remission, without another cause (subsequently must be confirmed by documenting ADAMTS13 activity &lt;10%)</td> </tr> <tr> <td class="indent2"> <ul> <li>ADAMTS13 relapse</li> </ul> </td> <td>ADAMTS13 activity &lt;20% following an ADAMTS13 remission</td> </tr> <tr> <td class="indent1">Exacerbation</td> <td>Recurrence of thrombocytopenia without another cause following a response but ≤30 days after stopping TPE or anti-VWF therapy</td> </tr> <tr> <td class="indent1">Refractory disease</td> <td>Lack of a clinical response to initial treatment*</td> </tr> </tbody></table></div><div class="graphic_lgnd">Refer to separate discussions in UpToDate for the approach to managing immune TTP, hereditary TTP, and other TMAs.

<ul class="decimal_heading">
<li>Clinical remission can occur without ADAMTS13 remission, but ADAMTS13 remission is always accompanied by clinical remission.</li>
<li>Clinical relapse is always accompanied by ADAMTS13 relapse, but ADAMTS13 relapse can occur without clinical relapse.</li>
<li>Preemptive treatment of ADAMTS13 relapse can induce ADAMTS13 remission and reduce the risk of clinical relapse.</li>
</ul>

Anti-VWF therapy includes caplacizumab and other therapies under development.</div><div class="graphic_footnotes">VWF: von Willebrand factor; TPE: therapeutic plasma exchange; LLN: lower limit of normal; DIC: disseminated intravascular coagulation.<br/>* Refractory disease is rare in the era of rituximab and anti-VWF therapy. If thrombocytopenia persists despite TPE, rituximab, and anti-VWF therapy, other potential causes such as sepsis, DIC, and drug-induced thrombocytopenia should be investigated.</div><div class="graphic_reference">Adapted from: Cuker A, Cataland SR, Coppo P, et al. Redefining outcomes in immune TTP: An international working group consensus report. Blood 2021; 137:1855.</div><div id="graphicVersion">Graphic 132744 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
